KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
for Carcinoma, Non-Small-Cell Lung
18 locations incl. Gilbert
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT04165070·Phase 1, Phase 2·Recruiting